Vaccine and blood test to prevent ovarian cancer return
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a personalized vaccine for people with epithelial ovarian cancer who still have a small amount of cancer DNA in their blood after surgery. The goal is to see if the vaccine can help stop the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II, III, or IV epithelial ovarian cancer that was removed with surgery
- You are between 18 and 70 years old
- A blood test after surgery shows a positive sign of minimal leftover cancer (ctDNA positive), but no other signs of cancer on scans or routine blood work
- Your overall health is good enough to follow the study plan and your doctor agrees it's safe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how changes in your immune system's T-cells (measured from blood samples) can help predict if ovarian cancer comes back. If you are newly diagnosed with advanced ovarian cancer and planning standard treatments (surgery plus chemo), you may join.
This study looks at how the immune system works in people with epithelial ovarian cancer. It aims to understand the immune landscape around the tumor, which could lead to better treatments in the future.
This trial studies a vaccine made from your immune cells (dendritic cell vaccine) given before chemotherapy and surgery. It aims to help your body recognize and fight ovarian cancer more effectively in people whose cancer is advanced and spread.
This study looks at immune-related markers in people with ovarian cancer to see if they can help predict prognosis (how the cancer may behave). If you qualify, your doctors may use your immune test results alongside other standard treatments like surgery, chemotherapy, and/or immunotherapy.
This trial tests a personalized vaccine (NeoOVSV) made from your tumor’s unique markers (neoantigens). It’s for women with Stage II or III epithelial ovarian cancer who had successful surgery to remove all visible cancer. The goal is to see if the vaccine is safe and helps your immune system fight any remaining cancer cells.
This trial tests a personalized vaccine made from your own immune cells and tumor mutations. It's for people with HRD-negative ovarian cancer who still have signs of cancer after standard treatment.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.